asco22 gynecologic oncology: relacorilant combined with nab-paclitaxel in recurrent ovarian cancer
Published 2 years ago • 408 plays • Length 5:06Download video MP4
Download video MP3
Similar videos
-
3:42
gynecologic oncology at asco 2022: athena–mono trial (rucaparib monotherapy) for ovarian cancer
-
1:19
relacorilant nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
-
0:46
gynecologic oncology at asco 2022: subgroup analysis of keynote-826
-
1:11
gyn onc at asco 2022: randomized phase iii trial on trabectedin in recurrent ovarian cancer
-
3:29
gynecologic oncology at esmo congress 2021: relacorilant, a phase 2 study
-
3:50
gynecologic oncology at asco 2022: tv pembro in first-line recurrent or metastatic cervical cancer
-
12:07
gynecologic oncology at asco21: novel targets in recurrent ovarian cancer
-
2:44
gynecologic oncology at asco 2022: session highlights to share with your patients
-
2:07
emerging therapies in gynecologic oncology at asco 2024
-
1:00:08
gyn gynecologic and ovarian cancer bcop 2021
-
7:46
expert report on novelties in the management of gynaecological malignancies from asco 2022
-
4:25
gynecologic oncology at esmo congress 2021: randomised phase ii trial of olaparib
-
4:34
gynecologic oncology at asco 2021: upfront therapy in ovarian cancer
-
15:12
understanding ovarian cancer
-
0:53
gynecologic oncology at asco 2018: ovarian cancer, jcog0602, onda
-
3:51
achieving a higher pcr rate with nab-paclitaxel in breast cancer
-
4:51
asco22 gyn cancer updates | dana chase, md, facog | arizona center for cancer care
-
21:18
surgical advances in ovarian cancer: what to watch